Advanced biomarker discovery for earlier diagnosis and improved prognosis of NAF...
Advanced biomarker discovery for earlier diagnosis and improved prognosis of NAFLD stages via high resolution mass spectrometry.
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of nearly 25% i.e., affects one quarter of the adult population. Early phase NAFLD is reversible and can be treated, but it may progress towards life-threatening st...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
RENAISSANCE
Advanced biomarker discovery for earlier diagnosis and impro...
150K€
Cerrado
mtFOIE GRAS
mitoFOIE GRAS Non invasive Profiling of Mitochondrial Funct...
455K€
Cerrado
LITMUS
Liver Investigation Testing Marker Utility in Steatohepatit...
47M€
Cerrado
ALIVE
Analytical platform for non-invasive diagnosis of LIVEr dise...
Cerrado
DeMILI
NON INVASIVE DIAGNOSTIC TEST SERVICE FOR NON ALCOHOLIC FATT...
71K€
Cerrado
PID2021-125394OA-I00
ESTADIFICACION NO INVASIVA DE LA ESTETATOHEPATITIS NO ALCOHO...
121K€
Cerrado
Información proyecto RENAISSANCE
Duración del proyecto: 25 meses
Fecha Inicio: 2023-05-16
Fecha Fin: 2025-06-30
Líder del proyecto
Masarykova univerzita
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
150K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of nearly 25% i.e., affects one quarter of the adult population. Early phase NAFLD is reversible and can be treated, but it may progress towards life-threatening stages such as non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC). The conventional diagnosis of NAFLD stages requires liver biopsy and is time-consuming and costly and there is an urgent need to identify biomarkers that can be applied in routine clinical settings, such as through blood-based testing. The identification of blood biomarkers would support earlier diagnosis and improved assessment of prognosis, ultimately supporting preventive/intervention measures to avoid progression to late stage liver disease and thus saving lives. In RENAISSANCE, a state-of-the-art liquid chromatography-high resolution mass spectrometry (LC-HRMS) metabolomics screening will be conducted upon the blood and blood-derived exosomes of a unique deeply phenotyped cohort of NAFLD patients for molecular biomarker discovery. Notably, exosome analysis shows promise for the identification of novel disease signatures but has yet to be applied to characterize NAFLD, providing high potential for the identification of new diagnostic/prognostic biomarkers for NAFLD. Furthermore, the LC-HRMS screen will be supported via targeted assays of redox metabolites and protein markers of acute inflammation. The integration of non-target and target data will provide insight into the underlying mechanisms of disease progression and further knowledge about potential causative factors of NAFLD.